We detected a significant elevation of serum HSP90a levels in pancreatitis patients and even more in pancreatic ductal adenocarcinoma (PDAC) patients. However, there was no significant difference in the serum HSP90a levels between patients with early-stage and late-stage PDAC. To study whether elevation of serum HSP90a levels occurred early during PDAC development, we used LSL-KrasG12D/Pdx1-Cre transgenic mice as a studying model. Elevated serum HSP90a levels were detected before PDAC formation and an extracellular HSP90a (eHSP90a) inhibitor effectively prevented PDAC development. Both serum HSP90a level and pancreatic lesion were suppressed when the mice were administered a CD11b-antagonizing antibody, suggesting that CD11b
C -myeloid cells. Duplex in situ hybridization assays suggested that macrophages were predominant HSP90a-expressing CD11b C -myeloid cells during PDAC development. Immunohistochemical and immunohistofluorescent staining results revealed that HSP90a-expressing cells included not only macrophages but also pancreatic ductal epithelial (PDE) cells. Cell culture studies also indicated that eHSP90a could be produced by macrophages and macrophage-stimulated PDE cells. Macrophages not only secreted significant amount of HSP90a, but also secreted interleukin-6 and interleukin-8 to induce a JAK2¡STAT3 signaling axis in PDE cells, stimulating them to express and secrete HSP90a. eHSP90a further promoted cellular epithelial-mesenchymal transition, migration, and invasion in PDE cells. Besides myeloid cells, eHSP90a can be potentially taken as a target to suppress PDAC pathogenesis.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) accounts for >95% of pancreatic malignancies and is one of the leading causes of cancer-related deaths in developed countries, with a 5-year survival rate <10% and a median survival as short as 6 months. 1 The retroperitoneal location of the pancreas and the undetectable small size of most precursor lesions hamper the early diagnosis of PDAC. Even if the tumor can be surgically resected, recurrence or metastasis often occurs, eventually resulting in an extremely poor outcome. Discovery of early-stage diagnostic markers and therapeutic targets is an urgent and important issue for this intractable disease.
Many molecular alterations are associated with the PDAC development. [2] [3] [4] For example, K-ras mutations, loss of p16 function, p53 inactivation, and Smad4 loss are found to occur in >90%, 90%, 50-75%, and 55% of PDAC patients, respectively. In transgenic mouse models, activating mutation in the K-ras gene is sufficient for the development of PDAC, [5] [6] [7] through a stage-by-stage process described as acinar/centroacinar cells ! acinar-to-ductal metaplasia (ADM) ! pancreatic intraepithelial neoplasia (PanIN) ! PDAC. 8 Investigation of clinical specimens has further suggested that rates of K-ras mutation in different stages are 0% (acinar cells), 63% (ADM), 74% (PanIN), and >90% (PDAC), respectively. 9 Because the whole process is accompanied by chronic inflammation in pancreas, 10, 11 immune-related tissue microenvironment reprogramming can occur early to facilitate K-ras mutations and initiate PDAC carcinogenesis. The presence of abundant myeloid cells in pancreas is therefore thought as an important hallmark of PDAC development.
Macrophages, neutrophils, and myeloid-derived suppressor cells (MDSCs) are the most common CD11b Supplemental data for this article can be accessed on the publisher's website. y These authors contributed equally.
infiltrating the tumor microenvironment. 12 Macrophage infiltration has been clinically correlated with metastasis in many malignancies including PDAC. [13] [14] [15] Earlier studies have demonstrated that tumor-infiltrating macrophages have tumoricidal activity. However, after interacting with tumor cells and other cells within the tumor microenvironment, macrophages release various cytokines and other factors that promote tumor cell migration, invasion, tumor angiogenesis, immune suppression, and tumor cell metastasis. [16] [17] [18] Macrophages are also involved in early stages of carcinogenesis by secreting RANTES, tumor necrosis factor-a (TNF-a), and heparin-binding epidermal growth factor to drive the process of ADM. 19, 20 Additionally, neutrophils are the most abundant granulocytes. Tumor-associated neutrophils may serve as the main producers of proangiogenic factors like matrix metalloproteinase (MMP)-9 during pancreatic carcinogenesis. 21 MDSCs play an important immunosuppressive role in tumor microenvironment, even though they exhibit high phenotypic and functional heterogeneities. Recently, granulocytic MDSCs (G-MDSCs), but not monocytic MDSCs, have found to be significantly increased in the tumor tissues of PDAC patients. 22 HSP90 is initially identified as a cellular chaperone aiding the proper folding, maturation, and trafficking of numerous client proteins such as ErbB2/Neu, HIF-1a, mutated p53, Bcr-Abl, Akt, and Raf-1. 23 Besides the localization at cytoplasm, nuclear HSP90 can regulate gene expression by interacting with RNA polymerase complex.
24 HSP90a can also be secreted from keratinocytes and cancer cells. [25] [26] [27] [28] [29] [30] Accumulating evidence shows that extracellular HSP90a (eHSP90a) can stimulate cancer cell malignancy through binding to cell-surface protein CD91. 26, [29] [30] [31] In colorectal cancer (CRC) cells, eHSP90a¡CD91 engagement elicits a NF-kB-dependent pathway to induce TCF12, integrin a V , and MMPs, promoting CRC cell epithelial-mesenchymal transition (EMT), migration, and invasion. 29, 30 CD91 can also interact with EphA2 co-receptor for eHSP90 to facilitate lamellipodial formation and subsequent motility and invasion of glioblastoma cells. 31 Recently, eHSP90a is also found to induce stemness in prostate cancer and CRC cells. 32, 33 Elevation of serum/plasma HSP90a levels has been detected in several malignancies including PDAC, non-small cell lung cancer, breast carcinoma, hepatocellular carcinoma, CRC, and glioblastoma. [27] [28] [29] [30] [31] In our present study, a significant elevation of serum HSP90a levels was detected from the patients diagnosed with pancreatitis or early-staged PDAC. Therefore, we wondered if elevation of HSP90a secretion occurred early during PDAC development, and if so, the biological functions involved were investigated. Because inflammation is closely associated with cancer development and malignant progression, we also studied the role(s) of myeloid cells in HSP90a secretion and PDAC development. To address these issues, transgenic mouse models and in vitro cell cultures were used.
Results

Elevation of serum HSP90a levels is associated with PDAC development
Clinically, higher HSP90a levels were detected in sera of pancreatitis patients compared with normal volunteers (0.57 § 0.23 vs. 0.18 § 0.05 mg/ml, P < 0.05, Fig. 1A ). More elevated serum HSP90a levels were detected in PDAC patients (1.04 § 0.86 mg/ml), although no significant difference was found between TNM stage-I/II patients and TNM stage-III/IV patients (1.08 § 0.93 vs. 0.96 § 0.69 mg/ml, P D 0.454), suggesting that elevation of serum HSP90a levels occurred early during PDAC development. To confirm this proposition, we investigated the change of serum HSP90a levels in LSLKrasG12D/Pdx1-Cre transgenic mice during their spontaneous PDAC development. Assessing the histopathological characteristics of pancreatic tissues, all (6/6) LSL-KrasG12D/Pdx1-Cre mice were observed to develop ADM and PanIN-1 lesions as early as 3 months after birth, while most (5/6) were observed to develop PDAC lesions at 6 months of age (Fig. 1B ). An obvious increase in HSP90a levels was detected in sera of 3-month-old mice, and this elevation was still evident at 6 months of age (Fig. 1C) . We next investigated if the increased eHSP90a was involved in the PDAC development. DMAG-N-oxide, 34 an eHSP90a inhibitor was administered to LSL-KrasG12D/Pdx1-Cre mice since 1 month after birth. Pancreatic tissues were histologically examined at 7 months of age. Pancreatic carcinogenesis was efficiently repressed by DMAG-N-oxide treatment (Fig. 1D) .
To confirm the participation of eHSP90a in PDAC development, C57 BL/6 mice that had been subcutaneously transplanted with Panc-02 cell grafts were treated with DMAG-Noxide. As expected, the tumor growth of Panc-02 cells was effectively attenuated by DMAG-N-oxide (Fig. 1E) . On Day-29 post-transplantation, the average tumor size of DMAG-Noxide-treated mice was significantly smaller than that of control mice with PBS treatment (0.06 § 0.04 vs. 0.17 § 0.07 cm 3 , P D 0.014). To further examine whether eHSP90a is involved in metastatic PDAC, C57 BL/6 mice were intravenously injected with Panc-02 cells and then treated with PBS or DMAG-Noxide. As metastatic pancreatic cancer leads to a poor prognosis, survival rates of the mice were recorded (Fig. 1F ). All 5 PBS-treated mice were died in 56 days after Panc-02 cell inoculation and tumor nodules were observed in their lungs (Fig. 1G , left panel). Two of them even had extra tumor masses adjacent to the lungs (Fig. 1G, right panel) . In contrast, DMAG-Noxide-treated mice exhibited no tumor nodules in lungs and survived longer than PBS-treated mice, except for one, which died on Day-43 with an obvious fight injury. Taken together, our data suggested that eHSP90a was not only associated with PDAC development but also with PDAC metastasis.
CD11b
C -myeloid cells are associated with PDAC development and elevation of serum HSP90a
In our LSL-KrasG12D/Pdx1-Cre mouse approach, CD11b C -myeloid cells were obviously detected in the pancreatic tissues at 3 months of age, without PDAC lesions ( Fig. 2A and B) . We wondered if infiltrating CD11b C -myeloid cells were involved in PDAC development and induction of serum HSP90a levels. Antibody clone M1/70, 35 an anti-CD11b monoclonal antibody was used to treat LSL-KrasG12D/Pdx1-Cre mice. This antibody efficiently suppressed the pancreatic infiltration of CD11b C -myeloid cells (Fig. S1 ). When 1-month-old mice were administered this antibody, their pancreatic tissues exhibited significantly fewer ADM lesions compared to mice administered a control IgG at 3 months of age ( Fig. 2C and D) . We also measured serum HSP90a levels in these mice when they were 1, 2, and 3 months of age. A significant elevation from 3-month-old LSL-KrasG12D/Pdx1-Cre mice administered control IgG was drastically suppressed when mice were administered anti-CD11b antibody (Fig. 2E) .
To further confirm the involvement of CD11b C -myeloid cells in elevation of serum HSP90a levels and tumor development, another transgenic mouse model with a CD11b-DTR-EGFP genotype was used. These mice were treated with diphtheria toxin (DT) for depletion of CD11b C -myeloid cells. As expected, Panc-02 cancer cell grafts did not significantly develop tumor masses (Fig. 2F) . The repression of tumor formation was not due to the direct inhibition of Panc-02 cell proliferation by DT, because there was no significant difference between the growth curves of Panc-02 cells with or without DT treatment (Fig. 2G) . In mice treated with mutant DT as a control, Panc-02 tumor masses were observed with green fluorescence, indicating the presence of tumor-infiltrating CD11b C -myeloid cells (Fig. 2H ). In accordance with these results, elevation of serum HSP90a levels was abolished in CD11b-DTR-EGFP mice administered wild-type DT but not mutant DT (Fig. 2I) . Taken together these observations, pancreas-infiltrating CD11b
C -myeloid cells were associated with elevation of serum HSP90a levels and PDAC development.
Macrophages account for most HSP90a-expressing myeloid cells during PDAC development
Macrophages and granulocytes are two common CD11b
Cmyeloid cells infiltrating PDAC tissues. Indeed, F4/80 C cells (macrophages) and Gr-1 C cells (granulocytes) were obviously detected at comparable levels in the pancreatic tissues of LSLKrasG12D/Pdx1-Cre mice at 3 months of age ( Fig. 3A and B) . Immunohistofluorescent staining was performed to investigate whether these cells could express HSP90a. As shown in Fig. 3C , most CD11b
C and F4/80 C cells (myeloid-derived macrophages) and a few CD11b
C and Gr-1 C cells (myeloid-derived granulocytes probably including G-MDSCs) were detected to express HSP90a. Given the Gr-1 antibody (RB6-8C5) mainly detected Ly6G with a weak cross-reactivity with Ly6C, we furthermore performed duplex in situ hybridization assays to confirm the status of HSP90a mRNA expression in F4/80 mRNA-expressing macrophages and Ly6G mRNA-expressing granulocytes. HSP90a-expressing CD11b
C -myeloid cells, F4/ 80 C -macrophages, and Ly6G
C -granulocytes were detected only in the pancreatic tissues of LSL-KrasG12D/Pdx1-Cre mice at 3 months of age but not in the pancreatic tissues of 1-monthold LSL-KrasG12D/Pdx1-Cre mice and 1-and 3-month-old LSL-KrasG12D mice (Fig. 4A) . The quantitative result indicated that the numbers of HSP90a
C cells, and Ly6G C cells were all increased significantly in the pancreatic tissues of 3-month-old LSL-KrasG12D/Pdx1-Cre mice (Fig. 4B) . A further analysis of the data indicated that HSP90a expression was detected in »80% of CD11b C cells, »50% of F4/80 C cells, and »22% of Ly6G C cells, respectively (Fig. 4C) . We also quantified the percentages of CD11b C cells, F4/80 C cells, and Ly6G C cells, respectively, from HSP90a-expressing cells. The data show that CD11b C -myeloid cells and F4/80 C -macrophages were both responsible for »57% of HSP90a C cells in the pancreatic tissues of 3-month-old LSLKrasG12D/Pdx1-Cre mice (Fig. 4D ), suggesting that macrophages were predominant HSP90a-expressing CD11b
C -myeloid cells during PDAC development.
Macrophages induced JAK2-STAT3-mediated HSP90a expression/secretion in HPDE cells
Clinically, we detected large amounts of macrophages from the cancer tissues of PDAC patients (Fig. S2A) . The infiltration level of CD68
C cells (pan-macrophages) was not significantly correlated with clinical parameters including patients' age, tumor size, tumor staging, and metastatic status, but higher infiltration levels of CD163 C cells (M2-type macrophages) were preferentially detected in the patients diagnosed with metastasis compared to the patients without metastasis (P D 0.013, Fig. S2B ). However, both levels of CD68
C and CD163 C cells were not correlated with serum HSP90a levels, suggesting that macrophage-expressed HSP90a alone could not sufficiently account for serum HSP90a levels. C -myeloid cells were detected in the tumor masses of mt DT-treated mice by using an IVIS imaging system. (I) HSP90a levels in sera of mice treated as described in (F). Sera were collected every week after the Panc-02 cell inoculation.
Apart from HSP90a in serum, we analyzed HSP90a expression in the pancreatic tissues of LSL-KrasG12D and LSLKrasG12D/Pdx1-Cre mice. Abundant HSP90a-expressing cells were detected in the pancreatic tissues of LSL-KrasG12D/Pdx1-Cre mice at 3 months of age but not from the pancreatic tissues of 1-month-old LSL-KrasG12D/Pdx1-Cre mice and 3-month-old LSL-KrasG12D mice (Fig. 5A) . Interestingly, these HSP90a-expressing cells included not only macrophages but also pancreatic ductal epithelial cells (Fig. 5A ). This phenomenon was also observed from patients' PDAC tissues (Fig. 5B) , suggesting that elevation of serum HSP90a levels could result from the expression and secretion of HSP90a from macrophages and macrophage-stimulated pancreatic ductal epithelial cells. To support this proposition, two human cell lines, pancreatic ductal epithelial cells (HPDE) and macrophages (differentiated THP-1), were cultivated and their culturing media were collected after 24 h. The average HSP90a levels in macrophage-culturing media and HPDE-culturing media were 60.54 § 3.29 mg/ml and 15.30 § 0.36 mg/ml, respectively (Fig. 6A) . Furthermore, when HPDE cells were pre-treated for 24 h with control medium or macrophage-conditioned medium (MfCM) and then incubated with fresh culture medium for another 24 h, the average HSP90a levels were significantly increased from 9.69 § 0.20 mg/ml to 44.59 § 2.68 mg/ml (P D 0.003, Fig. 6B ), suggesting that MfCM stimulated HPDE cells to secrete HSP90a.
We previously identified the components of MfCM which included inflammatory factors such as interleukin (IL)-8 (1851.5 pg/ml), TNF-a (29.5 pg/ml), and IL-6 (2.3 pg/ml). To determine if IL-8, TNF-a, and IL-6 were involved in MfCMstimulated HSP90a secretion, HPDE cells were treated with MfCM in the presence of IL-8 receptor-antagonizing antibody (IL-8RA), soluble TNF-a receptor 1 (sTNFR1), or soluble IL-6 receptor (IL-6sR). The effect of MfCM was significantly antagonized by IL-6sR and IL-8RA, especially by IL-6sR (Fig. 6B) . The JAK2¡STAT3 pathway is reported to be elicited by IL-6. Indeed, MfCM treatment induced cellular STAT3 phosphorylation, which could be repressed by IL-6sR (Fig. 6C) and JSI-124, a selective inhibitor of the JAK2¡STAT3 pathway (Fig. 6D ). mRNA and protein levels of HSP90a induced by MfCM were also suppressed by JSI-124 in HPDE cells (Fig. 6E) . Consistently, the increase of secreted HSP90a levels in culture media was abolished when HPDE cells were treated with MfCM in the presence of JSI-124 (Fig. 6F) . Together, these results suggest that macrophages did not only secrete HSP90a but also secreted IL-6 and IL-8 to induce the JAK2¡STAT3 pathway in HPDE cells to express and secrete HSP90a.
eHSP90a induces malignant transformation of HPDE cells
Next, we investigated whether eHSP90a could induce malignant transformation of HPDE cells. MfCM did not change the proliferative rate of HPDE cells in the absence or presence of the antibody antagozinig CD91 (Fig. 7A) . Purified recombinant C and F4/80 C cells (myeloid-derived macrophages) rather than CD11b C and Gr-1 C cells (myeloidderived granulocytes probably including G-MDSCs) in the pancreatic tissues of LSL-KrasG12D/Pdx1-Cre mice at 3 months of age.
HSP90a (rHSP90a) did not affect HPDE cell proliferation either (Fig. 7B) . Consistently, both MfCM and rHSP90a did not exhibit any significant effect on the cell-cycle phase distribution of HPDE cells (Fig. 7C) . The levels or activities of several key cell-cycle regulatory proteins were not significantly changed in rHSP90a-treated HPDE cells (Fig. 7D) . However, rHSP90a significantly stimulated anchorage-independent proliferation of HPDE cells (Fig. 7E) . Activation of FAK, a protein kinase related to cellular anchorage independence, with phosphorylations at Tyr-397 and Ser-722, was efficiently induced by rHSP90a, but was drastically inhibited by the antibody antagozinig CD91 (Fig. 7F) .
We next studied whether rHSP90a could induce EMT in HPDE cells. Cellular mRNA and protein levels of E-cadherin, connexin-26, and connexin-43 were downregulated under rHSP90a treatment, whereas mRNA and protein levels of fibronectin and EMT-inducing transcription factors such as TCF12, Twist-1, Snail, and Slug were induced in rHSP90a-treated HPDE cells (Fig. 8A) . Additionally, rHSP90a treatment repressed cellular gap-junction activity ( Fig. 8B and C) and promoted cellular outgrowth from 3-D spherical structures (Fig. 8D) . In vivo TCF12-expressing pancreatic cells which located at the invasive front edges of hyperplastic lesions originating from proliferating ductal epithelial cells were observed in control but not in DMAG-N-oxide-treated LSL-KrasG12D/ Pdx1-Cre mice (Fig. 8E) . These data together suggest that eHSP90a induced EMT in HPDE cells.
The effects of rHSP90a on HPDE cell migration and invasion were also investigated. The migration tracks of PBS-or rHSP90a-treated HPDE cells were monitored by time-lapse photography (Fig. 9A) . Quantification result showed that both accumulated and oriented migration distances were significantly increased in rHSP90a-treated HPDE cells compared with control cells (Fig. 9B and C) . Moreover, rHSP90a induced HPDE cell invasion as shown in conventional Matrigel invasion assay (Fig. 9D) . mRNA and protein levels of integrin a V , MMP-9, and MMP-2 were significantly induced in rHSP90a-treated HPDE cells; as expected, anti-CD91 antibody blocked this induction (Fig. 9E ).
Discussion
The chaperone protein HSP90a can be secreted by cancer cells under the microenvironment stresses like nutrient deficiency and hypoxia. 28, 29 Given that eHSP90a is an inducer of cellular EMT, migration, and invasion, the secretion of HSP90a can be thought as a strategy adopted by cancer cells to promote metastasis. Investigation of serum/plasma HSP90a levels and their relevance to clinical outcome is essential for evaluating the possibility of taking eHSP90a level as a marker of malignant progression. In our clinical study, a significant elevation of HSP90a levels was detected in sera of pancreatitis patients and even more in PDAC patients. However, there was no significant difference between low-staged and higher-staged PDAC patients, which was consistent with the result we had obtained from a cohort of 172 CRC patients. 29 We were therefore intrigued to study whether elevation of serum HSP90a levels occurred early during PDAC development. To confirm this, LSL-KrasG12D/Pdx1-Cre transgenic mice were measured serum HSP90a levels during their PDAC development process. LSL-KrasG12D/Pdx1-Cre mice developed pancreatic ADM within 3 months after birth, PanIN from 3 to 6 months after birth, and PDAC lesions after 6 months of age. A significant increase in serum HSP90a levels was found in these mice at 3 months of age, and it could still be detected after 6 months. Retardation of pancreatic carcinogenesis by DMAG-N-oxide further suggested an early involvement of secreted HSP90a in PDAC development. Besides secreted HSP90a, we also observed a significant elevation of cellular HSP90a expression in tumor tissues when compared with adjacent non-tumor tissues in almost all PDAC and CRC patients we have studied. The elevated HSP90a was also not correlated with patients' disease staging and survival. Analysis of another cohort of PDAC patients from the Oncomine database (Collisson Pancreas, GSE17891) also revealed no significant correlation between HSP90a mRNA expression level and overall survival of patients (95% confidence interval of hazard ratio D 0.60»1.40, P D 0.685). Taken together, an early and promoting role played by expression and secretion of HSP90a was suggested during PDAC development.
Change of tissue microenvironment has been known as a prerequisite for cancer development and metastasis. 36 Aside from HSP90a in sera, myeloid cell infiltration was abundantly detected in the pancreas of LSL-KrasG12D/Pdx1-Cre mice before PDAC lesions. Because pancreatic carcinogenesis is accompanied by chronic inflammation, inflammatory cells and their secretory factors can be involved in tissue microenvironment reprogramming to facilitate neoplasm formation and progression. Indeed, myeloid cells are known to secrete IL-6 to induce STAT3 activation in pancreatic cells in order to promote PanIN progression. 37 It has also been reported that macrophages secrete RANTES, TNF-a, and heparin-binding epidermal growth factor to drive ADM process. 21, 22 In our present study, two sets of transgenic mouse experiments were performed to demonstrate the involvements of CD11b C -myeloid cells and secreted HSP90a in PDAC development. First, LSL-KrasG12D/Pdx1-Cre mice were administered an antiCD11b antibody to block the pancreatic infiltration of CD11b C -myeloid cells were also required for the elevation of HSP90a levels in sera. Macrophages and granulocytes are two common tissueinfiltrating CD11b C -myeloid cells. Both of them were abundantly detected in the pancreatic tissues of LSL-KrasG12D/ Pdx1-Cre mice at 3-month age. The results of the duplex in situ hybridization suggested that macrophages rather than granulocytes accounted for most of the HSP90a-expressing CD11b C -myeloid cells during the PDAC development. Furthermore, we observed not only macrophages secreted HSP90a, but ductal epithelial cells secreted it as well in the pancreatic tissues of 3-month-old LSL-KrasG12D/Pdx1-Cre mice. Macrophages not only secreted significant amount of HSP90a, but also secreted IL-6 and IL-8 to induce the JAK2¡STAT3 signaling pathway in HPDE cells, stimulating them to express and secrete HSP90a. It is possible that other inflammatory cells can also activate pro-inflammatory cascades leading to HSP90a expression. Multiple cell sources of HSP90a could explain why pancreatic macrophage levels were not correlated with serum HSP90a levels in PDAC patients.
To study how eHSP90a promoted PDAC development, we investigated the effects of purified rHSP90a on HPDE cells. rHSP90a has been shown to increase cellular EMT, migration, and invasion in cancer cells via cell-surface receptor CD91. 26, [29] [30] [31] Consistent with these reported results, rHSP90a induced expression of transcriptional factors TCF12, Twist-1, Snail, and Slug, and also stimulated cellular EMT, migration, and invasion in HPDE cells, suggesting that rHSP90a was a potent inducer of malignancy in HPDE cells. It seems that in the pancreas with macrophage infiltration, secreted HSP90a acts in a paracrine or autocrine manner to induce tumorigeneity in ductal cells. It remains to be investigated if eHSP90a treatment can enhance the mutation rate of K-Ras gene in HPDE cells. Considering >90% of PDAC patients exhibit activated K-Ras mutants [2] [3] [4] and most K-Ras mutations may occur during ADM, 9 an inflammatory and stressful tissue microenvironment could be a niche for pancreatic ductal cells to acquire K-Ras mutations and further develop into PDAC-initiating cells.
In our study, the eHSP90a inhibitor DMAG-N-oxide efficiently prevented the PDAC development in LSL-KrasG12D/ Pdx1-Cre mice. For further therapeutic implications, DMAG-N-oxide efficiently retarded the tumor formation of subcutaneously injected cell grafts and the mortality caused by intravenously injected cancer cells, as well as the elevation of serum HSP90a levels. However, secreted HSP90a levels were recovered in these mice due to exhaustion of the DMAG-Noxide. The maximal tolerance dose of DMAG-N-oxide in C57 BL/6 mice was estimated to be 50»100 mg/g. The amount of 5 mg/g for each dose and 4 doses per mouse were considered as non-toxic to mice, but swollen spleens were observed in DMAG-N-oxide-treated Panc-02-transplanted mice. More studies are required to investigate further effects of eHSP90a and DMAG-N-oxide on immune cells. Recently, anti-HSP90a antibody has been reported to exhibit anti-cancer efficacies in CRC mouse models. 38 In view of this, several anti-HSP90a monoclonal antibodies have been developed and their efficacies against PDAC development and progression will be further evaluated.
In conclusion, pancreatic infiltration of myeloid cells is an early event leading to reprogramming of pancreatic tissue microenvironment for PDAC development. One underlying mechanism could be through production of eHSP90a that acts in an autocrine or paracrine manner to induce pancreatic ductal epithelial cells to acquire the characteristics of malignancy. Besides myeloid cells, eHSP90a can be potentially taken as a target to suppress PDAC pathogenesis.
Materials and methods
Clinical samples
Serum samples were collected from 10 healthy volunteers, 20 pancreatitis patients, and 114 PDAC patients at Taipei Veterans General Hospital (Taipei, Taiwan). Additionally, tissue sections from 99 PDAC patients were analyzed in this study.
Written informed consent was obtained from each sample donor in accordance with the medical ethics protocol approved by the Human Clinical Trial Committee of Taipei Veterans General Hospital.
Cell culture
Panc-02 mouse pancreatic cancer cells were cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM glutamine, and incubated at 37 C with 5% CO 2 in a humidified atmosphere. 39 Human HPDE cells were grown in keratinocyte serum-free (KSF) medium supplemented with bovine pituitary extract and epidermal growth factor (Life Technologies, Grand Island, NY, USA). 40 To collect HPDE-culturing medium (designated as HPDE-M), 2 £ 10 6 HPDE cells were seeded in a 10-cm plate and incubated with 10 ml of fresh medium. After incubation for 24 h, the medium was collected and filtered through a 0.45-mm filter for the subsequent measurement of secreted HSP90a. The medium collected from a plate that was set up in parallel but without HPDE cells was used as a control and designated as CTRL (KSF) . Human monocytic leukemia THP-1 cells were cultivated in minimal essential medium (MEM) supplemented with 10% FBS, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM glutamine. THP-1 cells (2 £ 10 6 cells per 10-cm plate) were induced by 100 ng/ml of 12-O-tetradecanoyl-13-phorbol acetate for 16 h to differentiate into macrophages. To collect macrophage-culturing medium (designated as Mf-M), 1 £ 10 6 macrophages were seeded in a 10-cm plate containing 10 ml of fresh MEM supplemented with 10% FBS, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM glutamine. After incubation for 24 h, the medium was collected and filtered through a 0.45-mm filter for the subsequent assay of secreted HSP90a. The medium collected from a plate without macrophages was used as a control and designated as CTRL (MEM) . For preparation of macrophage-conditioned medium (MfCM), 1 £ 10 6 macrophages were seeded in a 10-cm plate containing 10 ml of serum-free MEM. A plate containing serum-free MEM without macrophages was used in parallel as a control. After incubation for 24 h, media were collected, filtered through a 0.45-mm filter, and subsequently used as MfCM and control medium, respectively, to treat HPDE cells.
Transgenic mouse models
Breeders of LSL-KrasG12D and Pdx1-Cre transgenic mice were provided by the Mouse Models of Human Cancers Consortium Repository of the National Cancer Institute (Frederick, Maryland, USA). LSL-KrasG12D mice were crossed with Pdx1-Cre mice to generate LSL-KrasG12D/Pdx1-Cre mice. To investigate the role of eHSP90a in PDAC development, LSL-KrasG12D/ Pdx1-Cre mice were intravenously injected with three doses of PBS or 5 mg/g DMAG-N-oxide. The first dose was at 1 month of age, the second dose was 1 week after the first, and the final dose was given 2 weeks after the second. The mice were sacrificed at 7 months of age and the histopathological lesions in pancreatic tissues were examined. To explore whether CD11b C -myeloid cells were involved in PDAC carcinogenesis, LSLKrasG12D/Pdx1-Cre mice were intraperitoneally injected with 100 mg per injection of preimmune IgG or anti-CD11b antibody (clone M1/70; BioXcell, West Lebanon, NH, USA) at Days 28, 33, 38, 45, 52, 59, 66, 73, 80 , and 87 after birth (n D 5 for each group). These mice were sacrificed at 3 months of age, and pancreatic tissue sections were stained with H&E to identify ADM status. Additionally, breeders of CD11b-DTR-EGFP transgenic mouse were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). CD11b-DTR-EGFP mice were subcutaneously inoculated with 3 £ 10 5 Panc-02 cells; 3 days later, the mice were intraperitoneally injected thrice with 10 ng/g of wild-type or mutant DT at 3-daily intervals (n D 5 for each group). On Day-35 post-inoculation, tissue masses at the inoculation sites were surgically resected for analysis using IVIS Imaging System 200 Series (PerkinElmer Inc., Waltham, MA, USA).
Mouse tumor transplant models
The eHSP90a inhibitor, DMAG-N-oxide was produced and purified to a >95% purity by RDD Lab, Inc. ). Additionally, we investigated the effect of DMAG-N-oxide on the metastatic occurrence and mortality of the C57 BL/6 mice inoculated with Panc-02 cells (3 £ 10 5 cells per mouse) through tail-vein injection. The mice started to be treated with PBS or 5 mg/g DMAG-N-oxide (n D 5 per group) at 24 h post-inoculation. The second dose was given 24 h after the first, and the final dose was 48 h after the second. The survival rates of the treated mice were calculated by Kaplan-Meier method and analyzed by log-rank test.
Immunohistochemical staining
Paraffin-embedded tissue sections were deparaffinized in xylene, rehydrated through a series of ethanol dilutions, and boiled for 10 min in 10 mM citrate buffer, pH 6.0. Endogenous peroxidase activity was suppressed by exposure to 1% H 2 O 2 for 15 min. The tissue sections were then blocked with 5% BSA and incubated overnight at 4 C with antibodies against CD11b (Thermo Fisher Scientific, Rockford, IL, USA), F4/80 (AbD Serotec, Raleigh, NC, USA), Gr-1 (GeneTex Inc., Hsinchu City, Taiwan), mouse HSP90a (GeneTex Inc.), mouse CK-18 (Abcam, Cambridge, UK), and mouse TCF12 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibody detection was performed using the DAKO REAL EnVision Detection System (Produktionsvej 42, DK-2600 Glostrup, Denmark).
Immunohistofluorescent staining
Tissue sections with a 4-mm thickness were deparaffinized by xylene and then rehydrated by a series of ethanol dilutions. Antigen retrieval was carried out by heating 15 min in 10 mM citrate buffer, pH 6.0. The tissue sections were then blocked in 3% BSA in PBS for 30 min. For mouse tissue staining, the tissue sections were incubated overnight at 4 C with goat anti-CD11b antibody (1:100, Santa Cruz Biotechnology, sc-6614), rat anti-F4/80 antibody (1:100, AbD Serotec, MCA497R), and mouse anti-HSP90a antibody (1:100, Santa Cruz Biotechnology, sc-515081). After PBS washes, anti-goat IgG-Alexa Fluor 647 and anti-rat IgG-Alexa Fluor 594 antibodies (Invitrogen, Carlsbad, CA, USA) were applied. After incubation for another hour, Alexa Fluor 488 anti-Gr-1 antibody (1:80, Biolegend, #108417, San Diego, CA, USA) and anti-mouse IgG-DyLight 549 antibody (Rockland, Limerick, PA, USA) were applied and nuclei were stained with 4',6'-diamidino-2-phenylindole (DAPI). For human tissue staining, the tissue sections were incubated overnight at 4 C with mouse anti-CD68 antibody (1:100, Santa Cruz Biotechnology, sc-20060) and rabbit anti-HSP90a antibody (1:100, GeneTex Inc., GTX109753). After washes, antimouse IgG-Alexa Fluor 488 and anti-rabbit IgG-Alexa Fluor 568 antibodies (Thermo Fisher Scientific) and Alexa Fluor 647 anti-CK-18 antibody (1:100, Biolegend, #628404) were applied and nuclei were stained with DAPI. Results were observed and photographed under Leica TCS SP5 II confocal microscope and LASAF software (Leica, Wetzlar, Germany).
Duplex in situ hybridization
Mice were transcardially perfused with cold 4% paraformaldehyde in PBS. Paraffin-embedded pancreatic tissue sections with a 4-mm thickness were deparaffinized in xylene and rehydrated through a series of ethanol dilutions. RNA in situ hybridization was performed using the ViewRNA ISH Tissue 2-Plex Assay Kit (Affymetrix Inc., Santa Clara, CA, USA). Oligonucleotide probes were designed against HSP90a (NM_010480), Ly6G (NM_001310438), and F4/80 (NM_010130). Nuclei were stained with DAPI. The results were observed and photographed under a Leica TCS SP5 II confocal microscope and LASAF software. The thickness of the slide sectionedly scanned by lasering of confocal microscopy was 0.6»1.0 mm.
Immunoblot analysis
Cell lysate was prepared using lysis buffer consisting of 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4, 137 mM NaCl, 2.7 mM KCl, 0.5% deoxycholate, 1% NP-40, 0.3% SDS, and 1 mM phenylmethylsulfonyl fluoride. 29 Immunoblot analyses were performed according to the procedure described previously. 29 The antibodies used were specific for human STAT3, phosphorylated STAT3 (EMD Millipore, Billerica, MA, USA), HSP90a (AbD Serotec), phosphorylated FAK (Invitrogen), phosphorylated CDK2 (Epitomics, Burlingame, CA, USA), phosphorylated Rb, Rb, phosphorylated CDC2 (Cell Signaling, Danvers, MA, USA), connexin-43 (Sigma, St. Louis, MO, USA), integrin a V (BD Biosciences, San Jose, CA, USA), cyclin D1, MMP-2, MMP-9 (Lab Vision/NeoMarkers Co., Fremont, CA, USA), CDK4, cyclin E, cyclin A, CDK2, cyclin B1, CDC2, FAK, TCF12, Twist-1, Snail, Slug, E-cadherin, connexin-26, fibronectin, and GAPDH (Santa Cruz Biotechnology).
RT-PCR
Total RNA of treated HPDE cells was extracted using the Trizol reagent (Invitrogen). One microgram of RNA was subjected to reverse transcription using Moloney Murine Leukemia Virus reverse transcriptase (Finnzymes, Espoo, Finland). The resultant cDNA was used as the templates for PCR analyses. The primers and reaction conditions were listed in Table S1 . Realtime quantitative PCR (qPCR) was performed in a RotorGene 3000 system (Corbett Research, Mortlake, Australia) using SYBR Green PCR Master Mix (Cambrex Co., East Rutherford, NJ, USA), and the data were analyzed using RotorGene software v5.0.
Growth curve and cell-cycle phase analyses
HPDE cells were seeded in 6-well plates (1 £ 10 5 cells per well) and treated with PBS or 15 mg/ml rHSP90a for 1»5 days. After treatment, cells were trypsinized and suspended in PBS. Viable cells were immediately counted using a hemocytometer based on trypan blue dye exclusion. To analyze the cell-cycle phase distribution, PBS or rHSP90a-treated HPDE cells were trypsinized and fixed with -20 C pre-chilled 80% ethanol. After centrifugation, cell pellets were resuspended in 0.5% Triton X-100 for 5 min. Permeabilized cell suspensions were further staining with 1 ml of 50 mg/ml propidium iodide plus 0.5% (w/v) RNase A. Ten minutes later, the suspensions were filtered using Falcon 12 £ 75-mm polystyrene test tubes with 35-mm cell strainer Snap caps. The DNA content of cell samples was analyzed by a FACSCalibur flow cytometer with an argon laser at a 488-nm excitation (BD Biosciences).
Soft-agar colony formation assay
Two thousand HPDE cells were suspended in 1 ml of culture medium containing 0.3% agar plus PBS or 15 mg/ml rHSP90a and seeded into 6-well dishes pre-coated with 1 ml of 0.6% agar per well. These cells were incubated 21 days at 37 C, 5% CO 2 for the formation of cell colonies. Colonies (composed of 80 cells) were counted after Giemsa staining under the Olympus IX 71 inverted microscope (Center Valley, PA, USA).
Gap-junction activity assay
The dye Calcein can be transported between cells through gap junctions, and thus cellular gap-junction activity was evaluated by assaying the levels of Calcein transfer between cells. 30 HPDE cells treated with PBS or 15 mg/ml of rHSP90a were trypsinized and stained with Calcein acetoxymethyl ester and DiI (Invitrogen) for use as dye-donor cells. Donor cells were then added to a monolayer of unstained untreated HPDE cells (dye-recipient cells) at a ratio of 1:10 (donor/recipient). After co-culture for 0.2 or 3 h, the monolayer was washed, trypsinized, and resuspended in PBS and immediately analyzed using a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).
Assay of the invasive outgrowth from cell spheroids HPDE cells, mixed with culture medium plus 2% Matrigel (BD Biosciences), were seeded at a density of 1 £ 10 4 cells per well of 24-well dishes pre-coated with 250 ml of Matrigel. Fresh 2% Matrigel-supplemented medium was added every 2 days until cell spheroids formed. These cell spheroids were then treated 72 h with PBS or 15 mg/ml of rHSP90a in Matrigel-supplemented medium. Morphological (branching or budding) changes were observed under an Olympus IX 71 inverted microscope.
Cell migration and invasion assays
Time-lapse photometry was performed to assay cell migration. A monolayer of HPDE cells was wounded (through scratching) with a white tip, washed twice with PBS, and incubated at 37 C with fresh culture medium plus PBS or 15 mg/ml of rHSP90a for 24 h. The cells migrating into the wounded area were taken pictures every 10 min using a CCM-330F system (Astec Co., Fukuoka, Japan) and analyzed by the Image-Pro Plus version 5.0.2 software (MediaCybernetics Inc., Silver Spring, MD, USA). To assay cell invasiveness, HPDE cells treated 24 h with PBS or 15 mg/ ml of rHSP90a were suspended in 0.5% FBS-containing culture medium and seeded into the top chambers of Transwell inserts pre-coated with 5-fold diluted Matrigel. Cells were allowed to migrate for 16 h through the Matrigel toward the bottom chambers containing culture medium plus 10% FBS. The filters of the Transwell inserts were then fixed and stained with Giemsa. Invasive cells on the filters were imaged and quantified by the Image-Pro Plus software.
Statistical analysis
All experiments were performed independently at least three times. All data were calculated as mean § SD and statistical significance was determined with two-tailed Student's t-tests. Groups were considered significantly different when P < 0.05.
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